European Medicines Agency Revises Orphan Drugs Policy
EMA revises its polices on fee reductions for orphan drugs for 2014.
The European Medicines Agency has revised its policy on fee reductions for orphan drugs. The changes provide enhanced fee reductions for companies that are not micro, small, or medium-sized enterprises (SMEs) and will take affect on January 1, 2014. The policy will continue to focus on assistance to SMEs with the objective of providing incentives to support research and innovation on medicines intended for the diagnosis, prevention, or treatment of rare diseases, as recommended by EMA’s Committee for Orphan Medicinal Products (COMP). Current fee-reduction rates will still apply to applications received by EMA until Dec. 31, 2013.
EMA has listed the following fee reductions for non-SMEs in 2014:
- 75% fee reduction for non-pediatric-related initial and follow-up protocol assistance (currently a 40% fee reduction)
- 100% fee waiver for pediatric-related initial and follow-up protocol assistance (no change from 2013)
- 10% fee reduction for initial marketing-authorization applications (currently no fee reduction)
- 100% fee reduction for pre-authorization inspections (currently no fee reduction).
The following services will remain free-of-charge for SMEs in 2014:
- All initial and follow-up protocol assistance
- Initial marketing-authorization applications
- Pre-authorization inspections
- Post-authorization applications and annual fees in the first year of marketing authorization.
Source: European Medicines Agency
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
